Denali Therapeutics Inc. (DNLI) Misses Q4 EPS by 6c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q4 EPS of ($0.86), $0.06 worse than the analyst estimate of ($0.80).

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c